Chitty Lyn S, Lo Y M Dennis
UCL Institute of Child Health, Genetics and Genomic Medicine, London WC1N 1EH, United Kingdom; University College London Hospitals NHS Foundation Trust, London NW1 2PG, United Kingdom; NE Thames Regional Genetics Service, Great Ormond Street Hospital for Children NHS Foundation Trust, 37 Queen Square, London WC1N 3BH, United Kingdom.
Centre for Research into Circulating Fetal Nucleic Acids, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Shatin, NT, Hong Kong SAR, China; Department of Chemical Pathology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, NT, Hong Kong SAR, China.
Cold Spring Harb Perspect Med. 2015 Jul 17;5(9):a023085. doi: 10.1101/cshperspect.a023085.
The identification of cell-free fetal DNA (cffDNA) in maternal plasma in 1997 heralded the most significant change in obstetric care for decades, with the advent of safer screening and diagnosis based on analysis of maternal blood. Here, we describe how the technological advances offered by next-generation sequencing have allowed for the development of a highly sensitive screening test for aneuploidies as well as definitive prenatal molecular diagnosis for some monogenic disorders.
1997年,母体血浆中游离胎儿DNA(cffDNA)的发现预示着几十年来产科护理领域最重大的变革,基于对母体血液分析的更安全筛查和诊断应运而生。在此,我们描述了下一代测序技术的进步如何促成了一种对非整倍体高度敏感的筛查测试以及对某些单基因疾病的确定性产前分子诊断的发展。